The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company ...

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...

Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Eye drops can help soothe dry eyes by giving them much-needed hydration ... Buy now £8.99, Holland & Barrett Ocuvite Complete, Eye Supplement Capsules, by Bausch + Lomb From one of the world's leading ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on Bausch + Lomb Corporation (BLCO – Research Report). The ...

Trukera Medical, whose executive chairman is well-known Orange County executive Jim Mazzo, announced last month that it has been acquired by global eye health company Bausch + Lomb Corp. for an ...